FDA May Relassify ECT devices
Last Chance to Send Comments RE: Proposed Reclassification of ECTdevices
Last Chance to Send Comments RE: Proposed Reclassification of ECTdevices
A front page article in The New York Times raises the long-overdue alarms about the forced drugging of American children–in particular poor children who are condemned to ingest toxic neuroleptics (a.k.a. ‘atypical antipsychotics) at a rate four times higher than children whose parents have private insurance. These drugs qualify under…
Rather than having a deterrent effect, the number of Big Pharma high profile criminal settlements is increasing and the settlements are getting bigger.
TRUTHOUT reports: US Air Force Adds Kids to Pentagon’s MANDATORY H1N1 Vaccine Program
Corporate business ethics and investors’ interests have swept aside the humanitarian foundation of American medicine and most of related healthcare, and caring service professions.
In the first half of the twenty-first century, U.S. psychiatrists are prescribing the second generation neuroleptics—Zyprexa, Risperdal, Geodon, Seroquel, Abilfy—to coerce innocent children and the elderly into submission.
The case is so egregious that OHRP officials have taken the rare action of demanding that Columbia University track down the patients involved in the experiment and their families, and acknowledge that they never were informed about the “true nature” of the drug study, the risks they faced or the consequences of their participation.
America’s profit-driven medical paradigm overdiagnoses illness and garners profits from unnecessary treatment.
Dr. Joshua Sharfstein, the FDA’s principal deputy commissioner, acknowledged: “The message here is that there were problems with the integrity of F.D.A.’s decision-making process that have solutions.”
Big Pharma’s defense for its inequitable U.S. pricing is grounded on a Big Lie
"How can they call this America, the land of the free?" she asked. "Where are my parental rights?"
It is difficult to comprehend, why the Obama administration, which has made cost-cutting a legislative centerpiece of healthcare reform, would remove the most potent, financial penalty in its existing legal arsenal from its settlement with Pfizer.